Bendamustine and Rituxan for Waldenstrom’s – pro
he diagnosis in this case is small cell plasmacytic lymphoma. It is being used as bendamustine and Rituxan. Rituximab is widely used in WM patients (saem as plasmacytic lymphoma), due to single agent as well as combination studies in WM patients as well as other indolent B cell malignancies. Anti-CD20 monoclonal antibody therapy alone or in combination with chemotherapy is an important standard of care for most
patients with WM. The complete response rate for first-line bendamustine/rituximab is statistically noninferior to R-CHOP or R-CVP in indolent NHL or MCL. The safety profile of bendamustine/rituximab is distinct from that of R-CHOP/R-CVP but mpt worse.
Steven P. Treon How I treat Waldenström macroglobulinemia. Blood 2015 126:721-732
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen and John M. BurkeRandomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Blood 2014 123:2944-2952;